MISSISSAUGA, Ontario--(BUSINESS WIRE)--
MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce that Dr. Per Hall and Dr. Joe Walls, internationally renowned for their research on skin cancers and published authors of peer-reviewed research papers, have joined its Medical Scientific Advisory Board.
“We are very pleased to have Dr. Hall and Dr. Walls join our Medical Scientific Advisory Board. Both have been highly supportive of efforts in the early detection of skin cancers and of SIAscopy; their insights and guidance will result in our continuing to improve our skin scanning technology and thereby grow MedX’s business globally,” said Robert von der Porten, President & CEO of MedX.
Dr. Hall has been involved in image analysis for early detection of melanoma since the 1990s, initially as an Honorary Researcher in Computer Science at Birmingham University where he supervised BSC, MSC and PhD computer science projects. Having subsequently completed his training in Plastic and Reconstructive surgery he was appointed as an attending Consultant at the University Hospital in Cambridge UK (Addenbrookes Hospital NHS Foundation Trust). Much of this work has been published in scientific peer review journals or as bound Mastership theses. Dr. Hall has a number of skin and skin cancer related publications and helped write the first set of UK guidelines for the management of cutaneous melanoma.
Dr. Walls is a Consultant plastic surgeon working at North West Anglia Hospitals Trust in Cambridgeshire, England and is a member of the British Association of Plastic, Reconstructive and Aesthetic Surgeons and The British Association of Aesthetic Surgeons. Dr. Walls specializes in the diagnosis of skin cancer and surgical reconstruction, and has used SIAscopy in his practice for many years. Dr. Walls regularly speaks internationally on the topic of skin cancer and has also been involved in and authored many research project publications.
Dr. Hall and Dr. Walls live in the U.K.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005695/en/
